Synthesis of a Selective Orexin 1 Receptor Antagonist: First Scale-Up Campaign Following In-Licensing
Herein, we report the synthesis of 29.2 kg of the selective orexin 1 receptor antagonist C4X3256 monohydrate via a convergent 10-stage synthetic route. (S)-2-(Methylamino)-1-[5-(trifluoromethyl)-2-pyrazinylamino]propane was synthesized in 5 stages from l-alaninamide·HCl and isolated as the crystalline HCl salt. 6-Methyl-3-(2H-1,2,3-triazol-2-yl)pyridine-2-carboxylic acid was synthesized in 4 stages from 5-bromo-2-methylpyridine and isolated as the hemidiisopropylethylamine salt. The two advanced intermediates were combined in the final stage using T3P as a coupling reagent.
Authors
- Romain Claveau (ORCID: https://orcid.org/0000-0003-0681-6142)
- Maciej Mączka
- Gary F. Breen
- John S Carey (ORCID: https://orcid.org/0000-0002-3654-0063)
Institutions
- The Priory Hospital (GB)
- Almac (United Kingdom) (GB)
Publication Details
- Journal
- Organic Process Research & Development
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1021/acs.oprd.6c00444
- Citations
- 4
- Primary Topic
- Chemical Synthesis and Analysis
- Type
- article
- Field-Weighted Citation Impact
- 5.04
Funders
- National Institutes of Health
- National Institute on Drug Abuse